Clinical Therapeutics

Editorial comment
pp. 771-771(1)
Author: Walson P.D.

Current options for the prevention and treatment of migraine
pp. 772-788(17)
Authors: Adelman J.U.; Adelman R.D.

Review of oxymetholone: a 17-alkylated anabolic-androgenic steroid
pp. 789-801(13)
Authors: Pavlatos A.M.; Fultz O.; Monberg M.J.; Vootkur A.

Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease
pp. 802-832(31)
Author: Najib J.

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
pp. 833-850(18)
Authors: McGill J.B.; Reilly P.A.

Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia
pp. 851-857(7)
Authors: Branchi A.; Fiorenza A.M.; Torri A.; Muzio F.; Berra C.; Colombo E.; Valle E.D.; Rovellini A.; Sommariva D.

STATT: a titrate-to-goal study of simvastatin in asian patients with coronary heart disease
pp. 858-870(13)
Authors: Chung N.; Cho S.-Y.; Choi D.-H.; Zhu J.-R.; Lee K.; Lee P.-Y.; Lee S.-H.; Lee S.; Wang J.-J.; Yin W.-H.; Young M.-S.; Koh K.-K.; Son J.-W.; Sangwatanaroj S.; Panchavinnin P.; Phankingthongkum R.; Cai N.-S.; Fan W.-F.

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
pp. 871-885(15)
Authors: Ezzet F.; Krishna G.; Wexler D.B.; Statkevich P.; Kosoglou T.; Batra V.K.

Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study
pp. 886-900(15)
Authors: Solomon S.; Frishberg B.; Hu X.H.; Markson L.; Berger M.

A comparison of the skin permeation of three topical 0.5 0.000000luorouracil formulations with that of a 5 816242119941358331629659989308000000000000000.000000ormulation
pp. 901-907(7)
Authors: Levy S.; Furst K.; Chern W.

A pharmacokinetic evaluation of 0.5and 5 0.000000luorouracil topical cream in patients with actinic keratosis
pp. 908-920(13)
Authors: Levy S.; Furst K.; Chern W.

Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin
pp. 921-931(11)
Authors: Zussman B.D.; Kelly J.; Murdoch R.D.; Clark D.J.; Schubert C.; Collie H.

Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting
pp. 932-938(7)
Author: Walker J.B.

Enhancing the benefits of pharmaceuticals: what should states do?
pp. 940-941(2)
Author: Lyles A.

Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach
pp. 942-956(15)
Authors: Sauriol L.; Laporta M.; Edwardes M.D.; Deslandes M.; Ricard N.; Suissa S.

Responsiveness of the smoking cessation quality of life (SCQoL) questionnaire
pp. 957-969(13)
Authors: Shaw J.W.; Coons S.J.; Foster S.A.; Leischow S.J.; Hays R.D.

The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the First Myocardial Infarction Risk Reduction Program
pp. 970-980(11)
Author: Guthrie R.M.